You're Right to Test Symptomatic Patients—But Use Targeted Testing, Not Broad Multiplex Panels
For symptomatic college students with sore throat, fever, or lymphadenopathy, you should absolutely continue testing—but use targeted tests (rapid strep, Monospot, or single-pathogen PCR) as your first-line approach, not broad multiplex panels. The IDSA guidelines are crystal clear: testing is appropriate for symptomatic patients, but the test should match the clinical presentation 1.
Why Targeted Testing Makes Sense
The confusion here is about which test to use, not whether to test. Here's the algorithmic approach:
Step 1: Clinical Assessment Determines Testing Strategy
If viral features are present (cough, rhinorrhea, hoarseness, oral ulcers, conjunctivitis), skip bacterial testing entirely 1. These patients don't need any testing—it's viral.
If bacterial pharyngitis is suspected (sudden onset sore throat, fever, tonsillopharyngeal inflammation, tender anterior cervical nodes, absence of viral features), proceed with targeted GAS testing 1.
Step 2: Use Rapid Antigen Detection Test (RADT) First
- Rapid strep tests have >95% specificity 2, 3
- A positive RADT is diagnostic and allows immediate treatment
- Results in minutes, not hours
- Cost-effective and appropriate for point-of-care use
Step 3: Back-Up Culture for Negative RADTs (Age-Dependent)
- In college students (adults): A negative RADT generally does NOT require backup culture because the incidence of GAS and risk of rheumatic fever are low in adults 1
- Exception: Consider backup culture if high clinical suspicion persists despite negative RADT
Step 4: Consider Monospot for Appropriate Clinical Picture
If the presentation suggests infectious mononucleosis (prolonged fatigue, posterior cervical lymphadenopathy, splenomegaly, atypical lymphocytosis), add Monospot or EBV serology—but this is a targeted addition based on clinical features.
Why NOT Broad Multiplex Panels as First-Line
The evidence shows several problems with using broad respiratory multiplex panels for routine pharyngitis:
Cost and reimbursement issues: Many insurers restrict or don't cover broad multiplex panels for routine pharyngitis, potentially leaving patients with high out-of-pocket costs 4. Some Medicare Administrative Contractors require special documentation for these panels.
Detection doesn't equal causation: Multiplex panels detect 12-20 pathogens, many of which may be colonizers or incidental findings rather than the cause of current symptoms 5. A recent study found 74.5% detection rates with multiplex testing, but this included many viral detections that didn't change management 6.
Overtreatment risk: When you cast a wide net, you find things that don't need treatment. The key question is: will this result change management in a way that improves morbidity, mortality, or quality of life?
Guideline-directed care is targeted: IDSA guidelines specifically recommend rapid antigen testing for GAS, not broad panels 1, 3. The guidelines were designed to balance sensitivity, specificity, cost, and clinical utility.
The Real-World Algorithm
For a college student with sore throat and fever:
- Assess for viral features → If present, no testing needed
- If bacterial suspected → Rapid strep test
- If positive → Treat with penicillin or amoxicillin for 10 days 1
- If negative and low suspicion → No further testing, symptomatic care
- If negative but high suspicion → Consider throat culture (though less critical in adults)
- If mono suspected clinically → Add Monospot
Reserve multiplex panels for:
- Immunocompromised patients
- Severe illness requiring hospitalization
- Outbreak investigations
- When initial targeted testing is negative but clinical deterioration occurs
Common Pitfalls to Avoid
Don't test asymptomatic contacts of GAS cases—they don't need testing 1.
Don't use antistreptococcal antibody titers for acute pharyngitis diagnosis 1.
Don't order multiplex panels reflexively just because they're available—this drives up costs without improving outcomes 4, 5.
Don't skip the clinical assessment—testing everyone with any sore throat leads to overdiagnosis and overtreatment 3.
Bottom Line
You're absolutely correct that symptomatic patients need testing—that's good medicine. The issue is using the right test for the clinical scenario. Targeted testing (rapid strep, followed by culture if needed, plus Monospot when clinically indicated) is the evidence-based approach that balances diagnostic accuracy, cost-effectiveness, and antimicrobial stewardship 1, 3, 7. Broad multiplex panels should be reserved for specific clinical situations where they'll actually change management in ways that matter for patient outcomes.